Small-molecule PD-L1 inhibitor BMS1166 abrogates the function of PD-L1 by blocking its ER export
Therapeutic monoclonal antibodies against the PD-L1/PD-1 (programmed death ligand-1/programmed cell death protein-1) axis have achieved great successes in cancer treatments, but the development of small-molecule immunomodulators of the pathway has lagged far behind. We established a cellular cocultu...
Zapisane w:
| Główni autorzy: | , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Taylor & Francis Group
2020-01-01
|
| Seria: | OncoImmunology |
| Hasła przedmiotowe: | |
| Dostęp online: | http://dx.doi.org/10.1080/2162402X.2020.1831153 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|